1. Home
  2. OMER vs PSFE Comparison

OMER vs PSFE Comparison

Compare OMER & PSFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OMER
  • PSFE
  • Stock Information
  • Founded
  • OMER 1994
  • PSFE 1996
  • Country
  • OMER United States
  • PSFE United Kingdom
  • Employees
  • OMER N/A
  • PSFE N/A
  • Industry
  • OMER Biotechnology: Pharmaceutical Preparations
  • PSFE Business Services
  • Sector
  • OMER Health Care
  • PSFE Consumer Discretionary
  • Exchange
  • OMER Nasdaq
  • PSFE Nasdaq
  • Market Cap
  • OMER 513.8M
  • PSFE 599.1M
  • IPO Year
  • OMER 2009
  • PSFE N/A
  • Fundamental
  • Price
  • OMER $8.83
  • PSFE $6.80
  • Analyst Decision
  • OMER Strong Buy
  • PSFE Hold
  • Analyst Count
  • OMER 5
  • PSFE 5
  • Target Price
  • OMER $27.50
  • PSFE $10.60
  • AVG Volume (30 Days)
  • OMER 1.7M
  • PSFE 585.5K
  • Earning Date
  • OMER 11-13-2025
  • PSFE 11-13-2025
  • Dividend Yield
  • OMER N/A
  • PSFE N/A
  • EPS Growth
  • OMER N/A
  • PSFE N/A
  • EPS
  • OMER N/A
  • PSFE N/A
  • Revenue
  • OMER N/A
  • PSFE $1,683,103,000.00
  • Revenue This Year
  • OMER N/A
  • PSFE $3.24
  • Revenue Next Year
  • OMER N/A
  • PSFE $7.10
  • P/E Ratio
  • OMER N/A
  • PSFE N/A
  • Revenue Growth
  • OMER N/A
  • PSFE N/A
  • 52 Week Low
  • OMER $2.95
  • PSFE $6.66
  • 52 Week High
  • OMER $13.60
  • PSFE $24.11
  • Technical
  • Relative Strength Index (RSI)
  • OMER 67.40
  • PSFE 16.89
  • Support Level
  • OMER $6.24
  • PSFE $6.66
  • Resistance Level
  • OMER $7.06
  • PSFE $10.81
  • Average True Range (ATR)
  • OMER 0.54
  • PSFE 0.53
  • MACD
  • OMER 0.02
  • PSFE -0.40
  • Stochastic Oscillator
  • OMER 99.65
  • PSFE 2.45

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

About PSFE Paysafe Limited

Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.

Share on Social Networks: